BR112017019653B1 - Composto de formula i e composição farmaceutica - Google Patents

Composto de formula i e composição farmaceutica Download PDF

Info

Publication number
BR112017019653B1
BR112017019653B1 BR112017019653-0A BR112017019653A BR112017019653B1 BR 112017019653 B1 BR112017019653 B1 BR 112017019653B1 BR 112017019653 A BR112017019653 A BR 112017019653A BR 112017019653 B1 BR112017019653 B1 BR 112017019653B1
Authority
BR
Brazil
Prior art keywords
triazolo
pyridin
benzonitrile
cyano
methyl
Prior art date
Application number
BR112017019653-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017019653A2 (pt
Inventor
Saleh Ahmed
Gregory Barker
Hannah CANNING
Richard Davenport
David Harrison
Kerry Jenkins
David LIVERMORE
Susanne WRIGHT
Natasha Kinsella
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of BR112017019653A2 publication Critical patent/BR112017019653A2/pt
Publication of BR112017019653B1 publication Critical patent/BR112017019653B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112017019653-0A 2015-03-18 2016-03-17 Composto de formula i e composição farmaceutica BR112017019653B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
GB1504565.1 2015-03-18
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (2)

Publication Number Publication Date
BR112017019653A2 BR112017019653A2 (pt) 2018-05-15
BR112017019653B1 true BR112017019653B1 (pt) 2023-10-03

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019653-0A BR112017019653B1 (pt) 2015-03-18 2016-03-17 Composto de formula i e composição farmaceutica

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (2) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383747B (es) 2016-02-24 2025-03-14 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de quinasas janus (jak)
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
AU2020368368B2 (en) * 2019-10-14 2026-03-19 The Regents Of The University Of California Broad spectrum anti-cancer compounds
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso
CN115413277B (zh) * 2020-04-20 2023-08-01 深圳市塔吉瑞生物医药有限公司 吡嗪取代的烟酰胺的固体形式及其制备和用途
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023072240A1 (en) 2021-10-28 2023-05-04 Insilico Medicine Ip Limited Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
NZ523807A (en) 2000-06-30 2004-09-24 Wyeth Corp Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
US8283465B2 (en) * 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2011168582A (ja) 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
JPWO2014030716A1 (ja) 2012-08-23 2016-08-08 田辺三菱製薬株式会社 ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
JP2018512408A (ja) 2018-05-17
NZ735631A (en) 2023-07-28
DOP2017000209A (es) 2017-10-15
KR102609431B1 (ko) 2023-12-04
EP3271357A1 (en) 2018-01-24
AU2016234209B2 (en) 2020-08-27
CL2017002354A1 (es) 2018-05-04
CR20170468A (es) 2018-04-27
HK1249512A1 (en) 2018-11-02
IL254277A0 (en) 2017-10-31
WO2016148306A1 (en) 2016-09-22
ECSP17069696A (es) 2018-02-28
SG11201707280VA (en) 2017-10-30
PE20180656A1 (es) 2018-04-17
EA035739B1 (ru) 2020-08-03
EP3271357B1 (en) 2019-11-27
IL254277B (en) 2020-10-29
EA201792057A1 (ru) 2018-04-30
DK3271357T3 (da) 2020-02-17
PT3271357T (pt) 2020-02-21
GEP20207095B (en) 2020-04-10
ZA201706612B (en) 2019-01-30
PH12017501699B1 (en) 2023-06-30
ES2774052T3 (es) 2020-07-16
CA2979024A1 (en) 2016-09-22
UA123668C2 (uk) 2021-05-12
KR20170129874A (ko) 2017-11-27
PH12017501699A1 (en) 2018-03-12
MY194873A (en) 2022-12-21
JP6726681B2 (ja) 2020-07-22
US20180072714A1 (en) 2018-03-15
MX2017011902A (es) 2017-12-15
CN107531698B (zh) 2024-08-13
GEAP201914608A (en) 2019-10-10
CA2979024C (en) 2024-02-20
TN2017000384A1 (en) 2019-01-16
AU2016234209A1 (en) 2017-10-12
BR112017019653A2 (pt) 2018-05-15
CN107531698A (zh) 2018-01-02
GB201504565D0 (en) 2015-05-06
US10287286B2 (en) 2019-05-14
CO2017009353A2 (es) 2017-11-30
HUE047918T2 (hu) 2020-05-28

Similar Documents

Publication Publication Date Title
ES2774052T3 (es) Derivados de heteroarilo bicíclicos fusionados que tienen actividad como inhibidores de PHD
AU2020266529B2 (en) 3-amino-4H-benzo[E][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
ES2708211T3 (es) 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
WO2024255782A1 (zh) 双环衍生物parp抑制剂及其用途
KR20190092538A (ko) C-kit 억제제로서의 벤즈이미다졸 화합물
CA3084090A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
KR20190091537A (ko) C-kit 억제제로서의 아미노티아졸 화합물
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
CN104334532B (zh) 异喹啉和二氮杂萘衍生物
CN110088099A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法
AU2019225807A1 (en) Pharmaceutical combinations of EGFR inhibitors and methods of use thereof
KR20230112605A (ko) 키나아제 억제제 및 그의 용도
CN121889385A (zh) 作为因子b抑制剂的2-(1h-吲哚-4-基)甲基)2h-吲唑衍生物
CN104619707A (zh) 稠环杂环化合物
HK1249512B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
HK40123924A (en) 3-(6-pyridin-3-yl)-2-[4-(4-methyl-4h-1,2,4-triazol-3-yl)piperidin-1-yl]benzonitrile derivatives and similar compounds as qpctl and qpct inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFIQUE-SE, POR INCORRECAO NO QUADRO 1

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2016, OBSERVADAS AS CONDICOES LEGAIS